Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

Table 4

Results of subgroup analyses for overall survival.

Subgroup		HR	95% CI	Test of heterogeneity; -value	Test of heterogeneity; value	coefficient
Age
<65 years	1578	0.80	0.71–0.90			0%
≥65 years	1073	0.84	0.73–0.97			0%
Sex
Male	1604	0.82	0.73–0.92			48.59%
Female	1047	0.81	0.70–0.94			41.30%
ECOG status
0	1290	0.76	0.67–0.88			0%
≥1	1351	0.86	0.76–0.97			0%
KRAS status
Wildtype	1157	0.74	0.64–0.85			0%
Mutation	1260	0.89	0.78–1.02			0%